The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review

International Journal of Infectious Diseases

Volumn 13, Issue 6, 2009, Pages 663-667

  O'Horo, John ^a   Safdar, Nasia ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

CDAD; Clostridium difficile; Hypogammaglobulinemia; Immunoglobulin; IVIG

Indexed keywords

IMMUNOGLOBULIN; METRONIDAZOLE; PROBIOTIC AGENT; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; IMMUNOTHERAPY; INFECTION RATE; METHODOLOGY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PSEUDOMEMBRANOUS COLITIS; RELAPSE; REVIEW; SACCHAROMYCES BOULARDII; SAMPLE SIZE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED;

EID: 70349491503     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.11.012     Document Type: Review

References (37)

1. Bartlett J.G., and Perl T.M. The new Clostridium difficile-what does it mean?. N Engl J Med 353 (2005) 2503-2505
2. Morris Jr. J.G., Jarvis W.R., Nunez-Montiel O.L., Towns M.L., Thompson F.S., Dowell V.R., et al. Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders. Arch Intern Med 144 (1984) 967-969
3. Muto C.A. Asymptomatic Clostridium difficile colonization: is this the tip of another iceberg?. Clin Infect Dis 45 (2007) 999-1000
4. Rudensky B., Rosner S., Sonnenblick M., van Dijk Y., Shapira E., and Isaacsohn M. The prevalence and nosocomial acquisition of Clostridium difficile in elderly hospitalized patients. Postgrad Med J 69 (1993) 45-47
5. Paladino J.A., and Schentag J.J. The economics of Clostridium difficile-associated disease for providers and payers. Clin Infect Dis 46 (2008) 505-506
6. Song X., Bartlett J.G., Speck K., Naegeli A., Carroll K., and Perl T.M. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 29 (2008) 823-828
7. Vonberg R.P., Reichardt C., Behnke M., Schwab F., Zindler S., and Gastmeier P. Costs of nosocomial Clostridium difficile-associated diarrhea. J Hosp Infect 70 (2008) 15-20
8. Dallal R.M., Harbrecht B.G., Boujoukas A.J., Sirio C.A., Farkas L.M., Lee K.K., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235 (2002) 363-372
9. Prendergast T.M., Marini C.P., D'Angelo A.J., Sher M.E., and Cohen J.R. Surgical patients with pseudomembranous colitis: factors affecting prognosis. Surgery 116 (1994) 768-774 discussion 774-5
10. Pepin J., Valiquette L., and Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173 (2005) 1037-1042
11. Kenneally C., Rosini J.M., Skrupky L.P., Doherty J.A., Hollands J.M., Martinez E., et al. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest 132 (2007) 418-424
12. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
13. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005) 1079-1084
14. Gerding D.N., Muto C.A., and Owens Jr. R.C. Treatment of Clostridium difficile infection. Clin Infect Dis 46 Suppl 1 (2008) S32-42
15. Kyne L., Warny M., Qamar A., and Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 (2000) 390-397
16. Beales I.L. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhea. Gut 51 (2002) 456
17. Hassett J., Meyers S., McFarland L., and Mulligan M.E. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis 20 Suppl 2 (1995) S266-S268
18. Hassoun A., and Ibrahim F. Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. Am J Geriatr Pharmacother 5 (2007) 48-51
19. Jiang Z.D., Garey K.W., Price M., Graham G., Okhuysen P., Dao-Tran T., et al. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol 5 (2007) 964-968
20. Juang P., Skledar S.J., Zgheib N.K., Paterson D.L., Vergis E.N., Shannon W.D., et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 35 (2007) 131-137
21. Leung D.Y., Kelly C.P., Boguniewicz M., Pothoulakis C., LaMont J.T., and Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118 (1991) 633-637
22. McPherson S., Rees C.J., Ellis R., Soo S., and Panter S.J. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 49 (2006) 640-645
23. Murphy C., Vernon M., and Cullen M. Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 35 (2006) 85-86
24. Salcedo J., Keates S., Pothoulakis C., Warny M., Castagliuolo I., LaMont J.T., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41 (1997) 366-370
25. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhea. J Antimicrob Chemother 53 (2004) 882-884
26. Kyne L., and Kelly C.P. Prospects for a vaccine for Clostridium difficile. BioDrugs 10 (1998) 173-181
27. Mattila E., Anttila V.J., Broas M., Marttila H., Poukka P., Kuusisto K., et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 40 (2008) 702-708
28. Frost F., Craun G.F., and Calderon R.L. Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease. Emerg Infect Dis 4 (1998) 619-625
29. Gerber M., and Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin Investig Drugs 17 (2008) 547-553
30. McFarland L.V., Surawicz C.M., Greenberg R.N., Fekety R., Elmer G.W., Moyer K.A., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271 (1994) 1913-1918
31. Aboudola S., Kotloff K.L., Kyne L., Warny M., Kelly E.C., Sougioultzis S., et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71 (2003) 1608-1610
32. Kotloff K.L., Wasserman S.S., Losonsky G.A., Thomas Jr. W., Nichols R., Edelman R., et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 69 (2001) 988-995
33. Aslam S., Hamill R.J., and Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 5 (2005) 549-557
34. Knezevic-Maramica I., and Kruskall M.S. Intravenous immune globulins: an update for clinicians. Transfusion 43 (2003) 1460-1480
35. Kink J.A., and Williams J.A. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66 (1998) 2018-2025
36. Warny M., Fatimi A., Bostwick E.F., Laine D.C., Lebel F., LaMont J.T., et al. Bovine immunoglobulin concentrate-Clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 44 (1999) 212-217
37. Young K.W., Munro I.C., Taylor S.L., Veldkamp P., and van Dissel J.T. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile. Regul Toxicol Pharmacol 47 (2007) 317-326